Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.

Xianglin L DuLara M SimpsonBrian C TandyJudith L BettencourtBarry R Davis

Published in: PloS one (2021)

There were no statistically significant differences on the risk of hospitalized or non-hospitalized GI bleeding among the 3 ALLHAT trial arms (amlodipine, lisinopril, and chlorthalidone) during the entire in-trial follow-up.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
open label
angiotensin converting enzyme
atrial fibrillation
angiotensin ii
blood pressure
heart failure
placebo controlled
hypertensive patients